Choice ✔ investment

Choose stocks

Create and
share portfolios

Study reporting
public companies

ADPT - Company Financial Ratios

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests fo

United States
Healthcare Biotechnology NASDAQ | NasdaqGS

0 62.14

2021 62.14 8 349.88 - 33.34 0.00 0.00 11.63 0.000 0.00 0.61 73.41 - 14.69 - 23.40
2019 30.83 2 132.00 194.17 - 31.08 0.00 3.73 0.000 0.00 0.60 25.07 - 7.52 - 12.01